Many proteins involved in eukaryotic transcription are similar in function and in sequence between organisms. Despite the sequence similarities, there are many factors that do not function across species. For example, transcript elongation factor TFIIS is highly conserved among eukaryotes, and yet the TFIIS protein from Saccharomyces cerevisiae cannot function with mammalian RNA polymerase II, and vice versa. To determine the reason for this species specificity, chimeras were constructed linking three structurally independent regions of the TFIIS proteins from yeast and human cells. Two independently folding domains, II and III, have been examined previously using NMR (1-3). Yeast Domain II alone is able to bind yeast RNA polymerase II with the same affinity as the full length TFIIS protein, and this domain was expected to confer the species selectivity. Domain III has previously been shown to be readily exchanged between mammalian and yeast factors. However, the results presented here indicate that Domain II is insufficient to confer species selectivity, and a primary determinant lies in a 30 amino acid highly conserved linker region connecting Domain II with Domain III.
INTRODUCTION
In vivo, RNA polymerase II transcription units can vary from several hundreds to millions of base pairs, and these transcribed sequences contain information that regulates the elongation reaction for RNA polymerase II. Several types of blocks to elongation have been identified (4) and these include nucleosomes, DNA lesions, DNA binding proteins, and specific DNA sequences themselves. Thus, modulating the ability of RNA polymerase to recognize and overcome these blocks can regulate gene expression in the cell (4-7). Several proteins have been identified in vitro that affect transcript elongation by RNA polymerase II. One regulatory protein is TFIIS, a factor that enables RNA polymerase II to transcribe through a variety of blocks to elongation in vitro (4, 5, (8) (9) (10) (11) .
In mammalian cells, there is a family of TFIIS gene sequences, and these are expressed in a tissue or development specific pattern (12) (13) (14) (15) (16) (17) . In Saccharomyces cerevisiae the gene encoding TFIIS, PPR2 (18, 19) , is single copy but not essential. Disruption strains have several moderate phenotypes but are quite sensitive to the drug 6-azauracil (20) .
Across species, TFIIS proteins share a high degree of sequence conservation (21) .
Despite this similarity, S. cerevisiae does not function with metazoan polymerases and vice versa (22, 23) . Indeed, even S. pombe and S. cerevisiae do not stimulate each other's polymerases (21) . This species specificity is somewhat surprising given the striking similarity of amino acid sequences across these species in the functionally sufficient carboxy-terminal half of the protein (11). This region of TFIIS carries out all known functions in vitro, and these functions include stimulating an arrested RNA polymerase II to readthrough blocks to elongation by inducing the polymerase to hydrolyze mononucleotides or oligonucleotides from the 3' end of the nascent transcript (11). The carboxy-terminal half of TFIIS also is sufficient to complement the drug sensitivity of ppr2∆ strains in vivo (11, 22) .
Based on protease digestion studies and NMR structure analysis, yeast TFIIS consists of three major structural domains (1) (2) (3) . Domain I, the amino-terminal portion of TFIIS (amino acids 1-130 in yeast), shows the least relatedness across species. This region also is most divergent among the mammalian gene family members. Its function remains unclear as it is unnecessary for any known activities of the TFIIS protein (19, 24, 25) , although it can interact with at least one RNA polymerase II-containing protein complex (26) . This region of the yeast protein is also needed for complementing synthetic lethality observed between ppr2∆ and tfg3∆, although the reason for this requirement is not known (Davie and Kane, unpublished results). The four helix bundle structure of Domain I from yeast likely occurs in both Elongin A and CRSP30 (27) . This conservation suggests that each of these proteins may interact with the same target in the transcription complex.
The second domain of TFIIS, residues 131-240 in yeast, is α-helical (1,2).
Deletion analysis as well as site directed mutagenesis have shown that this region of the protein binds to the polymerase (27, 28, 30) . Indeed, Domain II from yeast binds to RNA polymerase II with the same affinity as the entire C-terminal fully functional portion of TFIIS (28) . Alanine scanning mutagenesis with human TFIIS characterized several positions, including K187A/K189A, in the Domain II region (24) that stimulated an arrested mammalian polymerase to cleave the nascent transcript, but not to read through a block to elongation (24). This result indicated that although cleavage is necessary for readthrough (31), it is not sufficient (24). This result also suggested that TFIIS may impart at least two functional changes on the polymerase.
The most highly conserved region of TFIIS lies within Domain III (residues 279-309) (3) (2). Mutagenesis has determined that Domain III is critical for TFIIS function (29, (32) (33) (34) . This region possesses a Zn ribbon motif that shares similarity to several small subunits of nuclear polymerases: RPB9 of RNA polymerase II, C11 of RNA polymerase III, and A12.2 of RNA polymerase I (3, (35) (36) (37) , as well as TFIIB (38) . This region is able to interact with nucleic acids in vitro although very weakly, and the functional significance of this interaction is not known.
Domains II and III are connected with a linker region of about 30 amino acids (2).
In yeast TFIIS, this linker region had no defined conformation based on NMR analysis, but also it was not fully flexible (2) . Furthermore, mutational studies with both human and yeast proteins demonstrated that residues in this region as well as their spacing were key to the function of TFIIS (28, 29, 33) .
The sequence and structural relatedness of human and yeast TFIIS proteins focused attention on the species specific interactions necessary for activity. The likelihood that Domain II was the determinant was supported by its ability to bind RNA polymerase II. Further, a yeast:murine chimera containing this region had been shown to function with the cognate polymerase (22) . However, these chimeras included both the linker region and Domain II, and thus a more complete series of chimeric constructions was made to evaluate the linker itself. The results highlight the functional importance of the linker amino acids between Domains II and III. Further, the results provide an explanation for the deleterious effect of mutations made in this region of the protein, and they reinforce the suggestion that the physical arrangement of Domains II and III when TFIIS encounters the ternary complex are critical for the readthrough stimulation by TFIIS. 
MATERIALS AND METHODS

Construction of human/yeast TFIIS mutants
The chimeric human/yeast TFIIS constructs were made by using standard PCR methods to amplify the desired fragments (39) . The PCR products were phosphorylated with polynucleotide kinase, digested with NdeI and BamHI, and ligated into pKC16 that had been also digested with NdeI and BamHI.
Plasmid pKC16 contains the upstream and downstream sequences flanking the genomic TFIIS open reading frame inserted into pRS 315 (40, 41) . Nomenclature and amino acids included in each TFIIS construction are listed in Table I .
Purification of mutant proteins
Chimeric TFIIS open reading frames were excised from the pKC16 based plasmids with BamHI and NdeI and ligated into pET15b-HMK (30) which had been similarly digested. Expression of these new open reading frames included both a His6 tag and heart myosin kinase site at the amino-terminus.
Overexpression of mutant proteins was as described by the manufacturer (Novagen) with the following modifications. BL21 cells were transformed with an expression plasmid.
LB with 100 µg/ml ampicillin was inoculated with a transformant. The culture was grown at 37 o C with shaking to an OD600 0.6-0.8. Overexpression was induced with 1mM IPTG for 3 hours at 30 o C with shaking. Cells were harvested by centrifuging for 5 minutes at 4 o C at 5000xg. Cell pellets were then flash frozen in a dry ice/ethanol bath.
One to two grams of cells were resuspended in 6 ml ice cold Binding buffer (5mM imidazole, 0.5M NaCl, 20mM Tris pH 7.9) with 0.1% Triton X-100 (Sigma) and Transformants from 1-1.5 ml of culture were collected by centrifugation. The cell pellet was washed with 1 ml 1X TE LiAc (10mM Tris pH 7.5, 1mM EDTA, 100mM LiAc) and then resuspended with less than 50 µl residual supernatant. To the resuspended cell mixture was added: 8 µg of single stranded carrier DNA (2mg/ml stock) that had been boiled for five minutes and placed on ice before using; approximately 1 µg of transforming plasmid (2-4 µl); and 300 µl of 1X PEG TE LiAc (40%PEG 3350 MW, 10mM Tris pH 7.5, 1mM EDTA, and 100mM LiAc). After mixing gently by pipetting, the yeast were incubated for 4-6 hours at room temperature, heat shocked for 15 minutes at 42 o C, washed twice with 1 ml water, resuspended in 250 µl of water, and plated on synthetic complete -ura -trp medium (43) .
Growth Assay with 6-azauracil The yeast strains used were CH1305 (MATα ade2 ade3 leu2 ura3 lys2) (44) and CMKY5 which was derived from CH1305 (MATa ade2 ade3 leu2 ura3 lys2 ppr2∆::hisG trp1∆::hisG URA3 hisG). Freshly streaked cells grown for three days at 30 o C were suspended in approximately 1 ml of sterile water and diluted to an OD600 of 0.1 and 0.01. Five µl of each dilution was placed on Synthetic Completeura -trp medium also containing 0 or 100 µg/ml 6-azauracil. The yeast were then incubated at 30 o C and monitored for growth. The 6-azauracil (Sigma) was dissolved in water at 6mg/ml and added to the medium at a final concentration of 100µg/ml.
Readthrough Assay
In vitro transcription was performed as described (25) to allow the polymerase to elongate along the template and form an arrested complex at one of the histone H3.3 arrest sites (45) . Then each reaction was incubated at 30 o C with TFIIS storage buffer (50mM Tris pH7.9, 10% glycerol, 50mM NaCl, 1mM DTT) or TFIIS wildtype or chimeric proteins at 5:1, 100:1, and 500:1 TFIIS:polymerase molar ratios.
Aliquots were taken at 5, 10, and 30 minutes. Each aliquot was treated as described (25) and resolved on a 6% acrylamide, 7M urea gel. Quantitation of bands was done with a Molecular Dynamics Phosphorimager system. The fraction of readthrough of the T1A site was calculated as (cpms run off RNA)/(cpms run off RNA + cpms T1A RNA).
Relative activity of chimeric to wildtype TFIIS proteins was calculated as (fraction readthroughchimeric -fraction readthroughbuffer only)/(fraction readthroughwtfraction readthroughbuffer only).
Cleavage Assay The cleavage assay was performed as described (25) . Purified, arrested transcription complexes were incubated at 30 o C with either TFIIS storage buffer (50mM Tris pH7.9, 10% glycerol, 50mM NaCl, 1mM DTT) or with wildtype or chimeric TFIIS proteins at 100:1, or, 500:1 TFIIS:polymerase molar ratios. Aliquots were taken at 1, 5, and 10 minutes. An additional aliquot was incubated with 1mM ATP, UTP, GTP, and CTP for 10 minutes at 30 o C and denoted as the "chase." All reactions were stopped as described (25) and resolved on 6% acrylamide, 7M urea gels.
Competition assay TFIIS was labeled with 32 P as described (29) 
RESULTS
Rationale
The goal of these studies was to derive a structural explanation for the functional species specificity of TFIIS to provide more information on the molecular mechanism by which TFIIS stimulates elongation by RNA polymerase II. The minimal active region of TFIIS was used as the baseline for activity comparisons (24,34). This region consists of structural Domain II, the flexible linker, and Domain III ( Figure 1 and (2)). Each of these regions was exchanged between the human and yeast TFIIS proteins to create a series of six chimeric proteins that were used in comparisons with proteins derived entirely from either the yeast or human TFIIS sequences (Table I ). The chimeras were tested for their ability to suppress the drug sensitivity of a ppr2∆ strain in vivo and to stimulate either yeast or mammalian RNA polymerase II to cleave the nascent transcript and read through a block to elongation in vitro.
This work made the initial assumption that the individual domains from human and yeast TFIIS proteins would fold independently. This assumption was based upon the structural studies of TFIIS (1) (2) (3) . That is, the structure of yeast TFIIS Domain II is the same either as a fragment (amino acids 131-238) or in the context of the minimally active form of TFIIS (amino acids 131-309) (1,2). Also, the NMR structure of a portion of Domain III from human TFIIS was virtually superimposable upon yeast TFIIS Domain
III (2,3).
Testing Domain II as the discriminator for species specificity
Previous mutagenesis indicated that Domain II of yeast TFIIS interacted with RNA polymerase II as well as did the fully active C-terminal half of TFIIS (amino acids 131-309). (29) . A separate study also had concluded that TFIIS bound to RNA polymerase II through Domain II and that this region of the TFIIS protein could distinguish polymerases from different organisms, a result explaining the species specific activity of the TFIIS protein (22) .
To test this hypothesis directly, two human/yeast TFIIS chimeras were constructed that exchanged only Domain II (Table II) . One chimera, yII-hL-hIII, consisted of residues 131-240 of yeast TFIIS (encompassing structural Domain II and denoted "yII") fused to human sequences (residues 233-301, denoted "hL-hIII") encompassing the human linker and Domain III. Chimera hII-yL-yIII was the reciprocal and included residues 131-232 of human TFIIS (denoted "hII") and the yeast linker and yeast Domain III (amino acids 241-309, denoted "yL-yIII"). As controls, ∆yTFIIS (yIIyL-yIII), residues 131-309 from yeast, and ∆hTFIIS (hII-hL-hIII), residues 131-301 from humans, were tested. Each of these constructs was fully functional with its cognate polymerase in vitro when compared to full length TFIIS (25) (24).
If Domain II was the sole specificity determinant, then yII-hL-hIII would function in yeast in vivo and stimulate yeast RNA polymerase II in vitro. In contrast, hII-yL-yIII would not be expected to function in yeast, and it would stimulate only mammalian RNA polymerase II in vitro. However, these predictions were not satisfied.
Only the hII-yL-yIII construct functioned detectably in vitro with yeast RNA polymerase II to promote readthrough ( Figure 2B, lanes 4-6 and 13-15) . The possible explanations for this observation are explored in more detail below.
Linker Region as Discriminator for Species Specificity
Additional chimeras (Table I) were constructed to test if the linker region or Domain III could be individually involved in species specificity determination (Table II) .
Terminology for the combined regions is presented in Figure 1B . A chimera analogous to hII-yL-yIII that has the murine Domain II and the linker equivalent functions effectively in vivo and in vitro with yeast RNA polymerase II (22) . Chimera hII-hL-yIII contained human Domain II and the human linker (residues 131-262, denoted "hII-hL") fused to the yeast Domain III. If the linker region determined species specificity, chimeras hII-yL-yIII and hII-yL-hIII would be able to complement a ppr2∆ strain in vivo and would stimulate yeast RNA polymerase II in vitro. In constrast, yII-hL-hIII and yII-hL-yIII, each with the human linker, would be expected to stimulate calf thymus polymerase in vitro.
All these chimeras were then tested in vivo and in vitro. Promoter independent transcription was performed (25) and arrested elongation complexes were subsequently incubated with TFIIS, TFIIS chimeras, or TFIIS storage buffer. Transcripts were resolved on denaturing polyacrylamide gels. In control experiments, wildtype ∆yTFIIS readily stimulated readthrough by yeast RNA polymerase II (Figure 2A lanes 1-5; (25) ), and, as expected, ∆hTFIIS had no detectable activity with the yeast enzyme (Figure 2A,   lanes 6-9) . Of the chimeras, yII-yL-hIII ( Figure 2B, lanes 1-3) , hII-yL-yIII ( Figure   2B , lanes 4-6), and hII-yL-hIII ( Figure 2B , lanes 7-9) had readily detectable readthrough activity. Chimera hII-yL-yIII was less active than wildtype ∆yTFIIS (compare Figure 2A , lanes 3 and 4 with Figure 2B, lanes 4 and 5) . Curiously, chimera hII-yL-hIII, that contained entirely human TFIIS sequences except for the yeast TFIIS linker region, also was able to facilitate detectable readthrough of the yeast polymerase in the same incubation period, but it required a 500:1 molar excess over polymerase ( Figure   2B, lanes 7-9) . In contrast, human/yeast chimeric TFIIS proteins, yII-hL-yIII, yII-hLhIII, and hII-hL-yIII were not able to stimulate detectable readthrough by yeast RNA polymerase II even at the 500:1 molar ratios ( Figure 2B, lanes 10-18 and data not shown). These results indicate that the linker region of yeast TFIIS is necessary to stimulate elongation by yeast RNA polymerase II, and the linker region contributes an essential part to the species specificity of TFIIS. Clearly, Domain II is not sufficient for conferring species specific activity on TFIIS.
Nascent transcript cleavage by RNA polymerase II is a necessary prerequisite for readthrough of blocks to elongation, and this cleavage reaction is stimulated by TFIIS (31, 46) . In addition, although cleavage is necessary for readthrough, it is not always sufficient (24,47). It was expected that the chimeric proteins would stimulate cleavage with yeast polymerase in parallel with effects observed during readthrough assays. Thus, wildtype ∆yTFIIS, yII-yL-hIII, hII-yL-yIII, and hII-yL-hIII were predicted to stimulate transcript cleavage by yeast RNA polymerase II. The cleavage assays were performed under the same conditions as the readthrough assays. The positive control, ∆yTFIIS, efficiently promoted transcript cleavage within the arrested complex ( Figure 3A compare lanes 1-4 with lanes 6-13) as did yII-yL-hIII ( Figure 3B, lanes 19-26) . Both chimera hII-yL-yIII and chimera hII-yL-hIII could stimulate transcript cleavage by the yeast polymerase although neither was as effective as the wildtype protein 
In vivo complementation
Next, each chimera was tested for complementation of the 6-azauracil drug sensitivity of the TFIIS disruption strain in yeast. If the yeast TFIIS linker region confers species specificity, then ∆yTFIIS, yII-yL-hIII, hII-yL-yIII, and hII-yL-hIII would be expected to function in vivo. Yeast strains deleted for the gene encoding TFIIS (ppr2∆) are more sensitive than wildtype strains to the drug, 6-azauracil (20) . Separate ppr2∆ strains containing a plasmid encoding one of the eight TFIIS proteins were patched onto synthetic medium with or without 6-azauracil and then grown for three days at 30 o C (Figure 4 ). Like ∆yTFIIS, chimera yII-yL-hIII was able to suppress the 6-azauracil sensitivity phenotype of the ppr2∆ yeast strain (Figure 4 ). This result was consistent with the in vitro experiments and has also been reported previously with a similar murine/yeast chimera (22) . Chimera hII-yL-yIII also complemented the ppr2∆ yeast strain (Figure 4 ).
The TFIIS proteins ∆hTFIIS, yII-hL-hIII, yII-hL-yIII, and hII-hL-yIII, inactive with yeast RNA polymerase II in vitro, also were unable to complement in vivo (Figure 4) . None of these proteins contained the yeast TFIIS linker region. However, while hII-yLhIII could stimulate yeast RNA polymerase II in vitro, it did not complement the disruption strain in vivo. This result was obtained when the chimera was expressed from either a low copy number or a high copy number plasmid. However, the question of protein levels in vivo remains to be resolved because sensitive and highly specific antibodies for the human protein are not available. All of these results indicate that the linker region is necessary but clearly not sufficient to confer full activity across species for TFIIS.
Binding to Yeast RNA Polymerase II
The original expectation was that exchange of Domain II alone would confer species specificity because of differences in binding to RNA polymerase II from the divergent species. Since the linker had been implicated in species specificity as well, the binding of the various chimeras to yeast RNA polymerase II was examined using a competition binding assay to determine which proteins were able to interact physically with yeast RNA polymerase II. Thus, radiolabelled y∆TFIIS and yeast RNA polymerase Table II ). The ∆hTFIIS protein promoted readthrough by mammalian RNA polymerase II, as expected ( Figure 6A, lanes 3-5) (24, 33, 48, 49) . Also as expected no stimulation of readthrough was detected when calf thymus polymerase was incubated with ∆yTFIIS, even when this protein was present at a 500-fold molar excess over the polymerase ( Figure 6A, lanes 6-8) .
Two chimeras that contained the human linker region (yII-hL-hIII and yII-hLyIII) had no detectable transcription stimulatory activity even at a 500-fold molar excess over the mammalian polymerase (data not shown). Even chimera hII-hL-yIII had barely detectable activity and only at the highest tested molar excess of factor over polymerase, 500:1 ( Figure 6A, lanes 9-11) . With the more sensitive cleavage assay, the same results were observed; that is, of all the chimeras, only hII-hL-yIII had detectable cleavage stimulatory activity ( Figure 6B ; summarized in Table II 
DISCUSSION
It was the purpose of this study to identify the portion of the TFIIS protein that was the determinant of species specificity. Not only the RNA polymerase II binding domain but also a rather unstructured region of about 30aa is necessary for the species specific activity of yeast TFIIS. TFIIS is not the only transcription factor that binds to RNA polymerase II and distinguishes between species. Human TFIIF can stimulate transcription by Drosophila RNA polymerase II, but yeast TFIIF can not substitute for mammalian TFIIF in an in vitro mammalian transcription system (J. Conaway, personal communication). Also, the RNA polymerase II CTD phosphatase from yeast cannot dephosphorylate the CTD on mammalian RNA polymerase II, and vice versa (50) . Further, there is a stimulatory effect of TFIIF on the phosphatase activity that is also species specific (50). The general transcription factor TFIIB that recruits RNA polymerase II to the promoter has been shown to be species specific (51) . While the ability to interact with the polymerase might be expected to be the central determinant in such species specific activity, the results reported here suggest that the entire explanation is more complex.
Domain swaps between human and yeast TFIIS proteins indicate that the linker region from residues 240-270 in yeast TFIIS is involved in species specific activity. This 30 amino acid region likely affects the functional arrangement between Domain II and Domain III of TFIIS and RNA polymerase II. Mutagenesis of residues within this linker region in both yeast and human TFIIS proteins suggests that many amino acids can be changed to alanine with little effect on activity (29, 33) . Some mutations in this region of the yeast protein actually confer tighter binding to RNA polymerase II while having reduced stimulation of cleavage and readthrough (29) . How much sequence flexibility is tolerated can be tested by further mutagenesis, especially of amino acids that are not conserved between the human and yeast TFIIS proteins.
Chimera hII-yL-hIII that consisted of human TFIIS sequence except for the linker region of yeast TFIIS most strikingly emphasizes the linker contribution to species specificity. This protein at high concentration was able to stimulate both cleavage and readthrough by yeast RNA polymerase II. Chimera hII-yL-yIII was even more effective in this stimulation and also complemented the yeast TFIIS disruption strain in vivo.
Although Domain II is responsible for binding to polymerase, it could not on its own confer species specificity because chimeras yII-hL-hIII and yII-hL-yIII were unable to stimulate yeast RNA polymerase II and could not complement a disruption strain for TFIIS in vivo.
Chimeric proteins with either yeast or human Domain II could compete with wildtype TFIIS for binding to the polymerase. This competition occurred whether or not the chimera was actually able to stimulate the polymerase in cleavage and readthrough.
However, these competition experiments also clearly showed that human Domain II was Perhaps Rpb9p is a target for the action of TFIIS Domain III, or it may communicate the signal from Domain II to the catalytic center of the polymerase. Alternatively, there may be critical nucleic acid contacts that occur between Domain III and the arrested ternary complex that not only stimulate the polymerase to cleave its nascent transcript but also to undergo a conformational change necessary for efficient readthrough. Understanding how the linker region of TFIIS contributes to its activity will provide insight into the elongation mechanism itself and will help in targeting subunits and residues of RNA polymerase II for studies on their particular functions in the cleavage and readthrough reactions that promote elongation. 
